Bovine valved xenograft conduits in the extracardiac Fontan procedure.

J Thorac Cardiovasc Surg

Department of Cardiovascular Diseases, King Faisal Specialist Hospital and Research Center, MBC-J 16, PO Box 40047, Jeddah 21499, Saudi Arabia.

Published: August 2003

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0022-5223(03)00126-0DOI Listing

Publication Analysis

Top Keywords

bovine valved
4
valved xenograft
4
xenograft conduits
4
conduits extracardiac
4
extracardiac fontan
4
fontan procedure
4
bovine
1
xenograft
1
conduits
1
extracardiac
1

Similar Publications

Background: Left atrial dissection is a rare and occasionally fatal complication of cardiac surgery and is defined as the creation of a false chamber through a tear in the mitral valve annulus extending into the left atrial wall. Some patients are asymptomatic, while others present with various symptoms, such as chest pain, dyspnea, and even cardiac arrest. Although there is no established management for left atrial dissection, surgery should be considered in patients with hemodynamic disruption.

View Article and Find Full Text PDF

Background: In small children with left atrioventricular valve dysfunction, valve repair is preferred but some will require valve replacement. No prosthetic valve has growth potential, bioprostheses have poor durability, and mechanical prostheses have high rates of thromboembolic and hemorrhagic complications. We reviewed our experience with a modified bovine jugular vein valve designed for use in the right ventricular outflow tract (Melody valve, Medtronic) and compared this with contemporary mechanical valve replacement.

View Article and Find Full Text PDF

Objective: The study objective was to investigate the effect of free-edge length on valve performance in bicuspidization repair of congenitally diseased aortic valves.

Methods: In addition to a constructed unicuspid aortic valve disease model, 3 representative groups-free-edge length to aortic diameter ratio 1.2, 1.

View Article and Find Full Text PDF

Valvular heart disease (VHD) poses a significant threat to human health, and the transcatheter heart valve replacement (THVR) is the best treatment for severe VHD. Currently, the glutaraldehyde cross-linked commercial bioprosthetic heart valves (BHVs) remain the first choice for THVR. However, the cross-linking by glutaraldehyde exhibits several drawbacks, including calcification, inflammatory reactions, and difficult endothelialization, which limits the longevity and applicability of BHVs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!